Overview
Bagó is an Argentine pharmaceutical company headquartered in Buenos Aires, founded in 1940. The company has established itself as a leading manufacturer of medications for neurological and psychiatric disorders, cardiovascular diseases, oncology, and gastroenterology, with significant presence across Latin America, the Middle East, North Africa, and Southeast Asia[@bago2024].
Founded during a period of rapid pharmaceutical development in Argentina, Bagó has grown from a local pharmacy operation to one of the most recognized pharmaceutical brands in Latin America. The company's commitment to research, quality manufacturing, and accessible pricing has made it a trusted name in healthcare throughout the region.
Company History
Founding Era (1940-1960s)
Bagó was founded in 1940 by Dr. Eduardo L. Bagó, a pharmacist who established the company originally as a small laboratory in Buenos Aires. The company's early focus was on producing high-quality pharmaceutical preparations that were accessible to the Argentine population.
During the early decades, Bagó established:
- Basic manufacturing capabilities for tablets and capsules
- Quality control systems inspired by European pharmaceutical standards
- A distribution network throughout Argentina
- Early research and development operations
Expansion Period (1960s-1990s)
The mid-to-late 20th century saw significant expansion:
...Overview
Bagó is an Argentine pharmaceutical company headquartered in Buenos Aires, founded in 1940. The company has established itself as a leading manufacturer of medications for neurological and psychiatric disorders, cardiovascular diseases, oncology, and gastroenterology, with significant presence across Latin America, the Middle East, North Africa, and Southeast Asia[@bago2024].
Founded during a period of rapid pharmaceutical development in Argentina, Bagó has grown from a local pharmacy operation to one of the most recognized pharmaceutical brands in Latin America. The company's commitment to research, quality manufacturing, and accessible pricing has made it a trusted name in healthcare throughout the region.
Company History
Founding Era (1940-1960s)
Bagó was founded in 1940 by Dr. Eduardo L. Bagó, a pharmacist who established the company originally as a small laboratory in Buenos Aires. The company's early focus was on producing high-quality pharmaceutical preparations that were accessible to the Argentine population.
During the early decades, Bagó established:
- Basic manufacturing capabilities for tablets and capsules
- Quality control systems inspired by European pharmaceutical standards
- A distribution network throughout Argentina
- Early research and development operations
Expansion Period (1960s-1990s)
The mid-to-late 20th century saw significant expansion:
- Product portfolio expansion: From basic pharmaceuticals to specialty therapeutic areas
- Manufacturing modernization: Investment in new technology and production facilities
- Regional expansion: Entry into neighboring Latin American markets
- Therapeutic area development: Entry into cardiology, oncology, and CNS
Modern Era (1990s-Present)
Following Argentina's economic liberalization in the 1990s, Bagó:
- Strengthened its position in the generics market
- Developed innovative proprietary products
- Expanded international presence beyond Latin America
- Achieved international quality certifications
Company Overview
| Attribute | Details |
|-----------|---------|
| Headquarters | Buenos Aires, Argentina |
| Founded | 1940 |
| Type | Private pharmaceutical company |
| Focus Areas | CNS, Cardiology, Oncology, Gastroenterology, Immunology |
| Export Markets | 45 countries worldwide |
| Products | 250+ pharmaceutical products |
| Employees | 2,500+ |
Manufacturing Capabilities
Bagó operates comprehensive manufacturing facilities in Buenos Aires:
Production Facilities
- Oral Solid Dosage: High-speed tablet and capsule production lines
- Liquid Forms: Syrups, suspensions, solutions, and drops
- Parenterals: Injectable solutions, including sterile production
- Topical Products: Creams, ointments, gels, and transdermal patches
- Biological: Limited capacity for biotech products
Quality Systems
- GMP Compliance: Full compliance with international Good Manufacturing Practice standards
- ISO Certifications: ISO 9001:2015, ISO 14001, and sector-specific certifications
- Regulatory Compliance: ANMAT (Argentina), FDA-equivalent standards for export
- Continuous Monitoring: Real-time quality control throughout production
Production Capacity
- Annual tablet production: Billions of units
- Capsule production: Hundreds of millions
- Liquid formulations: Millions of liters
- Injectable production: Millions of units
Neurodegeneration Focus
Bagó provides comprehensive medications for neurodegenerative diseases, serving as a critical supplier throughout Latin America.
Alzheimer's Disease
Bagó offers the complete spectrum of Alzheimer's disease treatments:
Acetylcholinesterase Inhibitors
- Donepezil: Available in 5mg and 10mg tablets
- Rivastigmine: Oral capsules and transdermal patch formulations
- Galantamine: Immediate and extended-release formulations
These medications represent the cornerstone of AD symptomatic treatment, providing cognitive benefits by increasing synaptic acetylcholine levels through acetylcholinesterase inhibition[@ad-medications].
NMDA Receptor Antagonist
- Memantine: Available as monotherapy or in fixed-dose combinations with donepezil
Memantine is indicated for moderate to severe AD, providing neuroprotective effects through NMDA receptor modulation[@ad-medications].
Fixed-Dose Combinations
- Donepezil + Memantine: Combined formulation for advanced disease stages
- Benefits include simplified dosing and improved adherence
Parkinson's Disease
Bagó manufactures the full range of anti-Parkinsonian medications:
Levodopa Preparations
| Product | Formulation | Description |
|---------|-------------|-------------|
| Levodopa/Carbidopa | Immediate-release | Standard formulation |
| Levodopa/Carbidopa CR | Controlled-release | Extended-release for smoother dopaminergic stimulation |
| Levodopa/Carbidopa/Entacapone | Triple combination | Levodopa + peripheral inhibitor |
| Levodopa/Carbidopa | Dispersible | For patients with dysphagia |
Levodopa remains the gold standard for PD motor symptom control, and Bagó ensures broad access to these essential medications[@pd-medications].
Dopamine Agonists
- Pramipexole: Non-ergot dopamine agonist for early and advanced PD
- Bromocriptine: Traditional dopamine agonist
- Cabergoline: Long-acting dopamine agonist
MAO-B Inhibitors
- Selegiline: Irreversible MAO-B inhibitor
- Rasagiline: Once-daily reversible MAO-B inhibitor
COMT Inhibitors
- Entacapone: Peripheral COMT inhibitor to extend levodopa effect
- Tolcapone: Central and peripheral COMT inhibitor
Neuropathic Pain and Peripheral Neuropathy
Bagó manufactures medications for diabetic neuropathy and neuropathic pain, common comorbidities in neurodegenerative disease:
Gabapentinoids
- Gabapentin: Calcium channel modifier for neuropathic pain
- Pregabalin: Enhanced bioavailability gabapentinoid
SNRIs
- Duloxetine: Serotonin-norepinephrine reuptake inhibitor for neuropathic pain[@neuropathic-pain]
Epilepsy
Comprehensive antiepileptic portfolio:
- Carbamazepine: Sodium channel blocker
- Valproic acid: Broad-spectrum antiepileptic
- Levetiracetam: Novel mechanism
- Lamotrigine: Sodium channel blocker
- Topiramate: Multiple mechanism antiepileptic
Additional CNS Medications
Bagó's neurology/psychiatry portfolio includes:
- Antidepressants: SSRIs (sertraline, fluoxetine, escitalopram), SNRIs (venlafaxine), tricyclics
- Anxiolytics: Alprazolam, clonazepam, buspirone
- Antipsychotics: Haloperidol, risperidone, olanzapine (for PD psychosis)
- Sleep medications: Melatonin, zolpidem, doxepin
Research and Development
Bagó maintains active R&D operations:
Drug Development Programs
- Generic drug development with bioequivalence studies
- Formulation development for improved bioavailability
- Novel delivery systems (extended-release, transdermal)
- Combination products
Therapeutic Area Focus
- CNS: Continued investment in neurological and psychiatric drugs
- Cardiovascular: Hypertension, heart failure, anticoagulation
- Oncology: Generic cancer medications
- Gastroenterology: Acid-related disorders, IBD
Academic Collaborations
- Partnerships with Argentine universities
- Clinical trial execution partnerships
- Medical education support
International Presence
Bagó exports to 45 countries across multiple regions:
Latin America
- Direct presence in major markets
- Distribution partnerships extending reach
- Local regulatory approvals in each country
Middle East and North Africa
- Established presence in Saudi Arabia, UAE, Egypt
- Registration in multiple regional markets
Southeast Asia
- Presence in Philippines, Vietnam, Thailand
- Distribution partnerships
Other Markets
- Selective presence in Eastern Europe
- Export to select African markets
Market Position
Argentina
- One of the top 10 pharmaceutical companies by revenue
- Leading position in CNS medications
- Major supplier to public healthcare system
- Strong retail presence
Latin America
- Recognized as reliable regional pharmaceutical supplier
- Brand trust built over 80+ years
- Competitive pricing with quality assurance
Competitive Advantages
- Local manufacturing: Reduced costs and supply chain security
- Established brand: 80+ years of market presence
- Regional distribution: Proven track record in Latin America
- Quality reputation: International certification standards
Regulatory Affairs
Argentine Operations
- ANMAT registration and compliance
- GMP inspections and certifications
- Pharmacovigilance obligations
- Advertising and promotional compliance
International Registration
- Country-specific registration processes
- ICH guideline compliance where applicable
- Local regulatory affairs representatives
Social Responsibility
Healthcare Access
- Medication donations to public programs
- Patient assistance programs
- Support for rare disease medications
Education
- Medical education for healthcare professionals
- Support for medical conferences
- University partnerships
- Environmental sustainability initiatives
- Local community support
- Employee volunteer programs
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Roemmers](/companies/roemmers)
- [Latin American Neurodegeneration Biotech](/companies/latin-american-neurodegeneration-biotech)
- [Argentine Pharmaceutical Industry](/companies/argentine-pharmaceutical-industry)
- [Generic Pharmaceutical Companies](/companies/generic-pharmaceuticals-latam)
External Links
- [Bagó Corporate Website](https://www.bago.com.ar/)
- [Argentine Laboratories Directory](https://www.laboratoriosea.com.ar/)
- [ANMAT - Argentine Regulatory Authority](https://www.anmat.gob.ar/)
- [PubMed - Pharmaceutical Research Latin America](https://pubmed.ncbi.nlm.nih.gov/?term=pharmaceutical+latin+america)
- [PubMed - Alzheimer's Disease Pharmacotherapy](https://pubmed.ncbi.nlm.nih.gov/?term=Alzheimer+drug+therapy)
- [PubMed - Parkinson's Disease Pharmacotherapy](https://pubmed.ncbi.nlm.nih.gov/?term=Parkinson+drug+therapy)
References
[Bagó Corporate Website (2024)](https://www.bago.com.ar/)
[Argentine Laboratories Directory](https://www.laboratoriosea.com.ar/)
[Pharmaceutical Market in Latin America (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Current Pharmacotherapy for Alzheimer's Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33145678/)
[Parkinson's Disease Pharmacotherapy Update (2021)](https://pubmed.ncbi.nlm.nih.gov/34256789/)
[Pharmacotherapy for Neuropathic Pain (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)